Atlas Trials

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

Clinical trial NCT01156415 · TERMINATED

Trial details

NCT number
NCT01156415
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Major Depressive Disorder
Start date
2010-06-01
Primary completion
2011-10-01
Enrollment
837

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.